Skip to main content
. 2010 Mar 17;17(1):18. doi: 10.1186/1423-0127-17-18

Figure 3.

Figure 3

Effect of the Akt inhibitor AKTi-1/2 on mRNA levels for the MafK, SytI, and Syn-1 genes. (A) Western blot analysis of pAkt(Ser-473) protein level in PC12 (WT-Akt) cells treated with various concentrations of AKTi-1/2 prior to 10 min treatment with NGF. (B) The percentage of neuritogenic PC12 (WT-Akt) cells treated with or without AKTi-1/2. Averages and standard deviations are derived from more than six fields of view. *P < 0.001 (n = 6-9, mean + SD). (C) Semi-quantitative RT-PCR. PC12 (WT-Akt) cells were treated with various concentrations of AKTi-1/2. (D) Quantitative RT-PCR. PC12 (WT-Akt) cells were treated with 10 μM of AKTi-1/2. The mRNA level is presented as a fold difference over that of vehicle-treated cells. *P < 0.05 (n = 3-4, mean + SD). (E) Western blot analysis of SytI and Syn-1 protein levels in PC12 (WT-Akt) cells treated with vehicle (Veh) or 10 μM AKTi-1/2.